SELSYM BIOTECH INC

Cary, NC · Biotech · Private

Synthetic platelet-like particles (microparticles with fibrin-targeting antibodies) for hemostasis and wound healing

Grants
$1.3M
5 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Evaluation of stability and safety of platelet-like particles for treating bleeding after trauma$254,878
Federal grantDepartment of Health and Human Services · Phase I · Evaluation of stability and safety of platelet-like particles for treating bleeding after trauma$254,878
Federal grantDepartment of Health and Human Services · Phase I · Increasing efficiency of sdFv production in a tobacco-based system for synthetic platelet design$258,501
Federal grantDepartment of Health and Human Services · Phase I · Increasing efficiency of sdFv production in a tobacco-based system for synthetic platelet design$258,501
Federal grantDepartment of Health and Human Services · Phase I · SymHeal: A novel therapy for treating non-healing diabetic ulcers$229,474
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1385STRESS THERAPEUTICS, INC.——
1386Atrapos Therapeutics, LLC——
1387Mycosynthetix, Inc.——
1388SELSYM BIOTECH INC——
1389NAWGEN, LLC——
1390VIVREON BIOSCIENCES LLC——
1391GROVE BIOPHARMA, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.